CIPLANSECipla Limited· PharmaceuticalsMediumNeutral
Announced Wed, 13 May · 13:22 IST

Cipla Limited has informed the Exchange regarding grant of stock options and the employee stock appreciation rights .

Corporate Actions View source PDF

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.9%1-day move
₹1293.70
prior close
₹1346.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.3-0.2+0.1+10.9+10.4+10.2+8.9+8.2+7.7+8.4+6.8+10.3
Up moveDown movePending
AI summary

Cipla's Board of Directors approved the grant of stock options and employee stock appreciation rights (ESARs) under two schemes. Under the Employee Stock Option Scheme 2013-A, 176,389 stock options were granted with vesting periods of 1-2 years at an exercise price of INR 2 per option. Under the ESAR 2021 scheme, 596,244 ESARs were granted with vesting periods of 1-3 years at an exercise price of INR 2 per share. All grants have an exercise period of 5 years from the vesting date. The Board also approved convening the 90th AGM on 25th June 2026, appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27, and appointment of Mr Sushrut Kulkarni as President & Global Chief – Integrated Product Development effective 18th May 2026.

Likely market impact

This is a routine employee compensation announcement. The stock option grants align employee interests with shareholders but result in modest dilution. The exercise price of INR 2 is significantly below market, which may impact future earnings per share upon exercise. No direct impact on near-term stock price expected.